These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 29366843)
21. Cardiomyopathy associated with iron overload: how does iron enter myocytes and what are the implications for pharmacological therapy? Wijarnpreecha K; Kumfu S; Chattipakorn SC; Chattipakorn N Hemoglobin; 2015; 39(1):9-17. PubMed ID: 25572185 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Thephinlap C; Phisalaphong C; Fucharoen S; Porter JB; Srichairatanakool S Med Chem; 2009 Sep; 5(5):474-82. PubMed ID: 19534681 [TBL] [Abstract][Full Text] [Related]
23. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice. Kumfu S; Chattipakorn S; Srichairatanakool S; Settakorn J; Fucharoen S; Chattipakorn N Eur J Haematol; 2011 Feb; 86(2):156-66. PubMed ID: 21059103 [TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Suzuki S; Ohkusa T; Ono K; Sato T; Yoshida MA; Yano M; Takebayashi S; Matsuzaki M Circ J; 2007 Dec; 71(12):1970-6. PubMed ID: 18037756 [TBL] [Abstract][Full Text] [Related]
25. Green tea extract modulates oxidative tissue injury in beta-thalassemic mice by chelation of redox iron and inhibition of lipid peroxidation. Koonyosying P; Kongkarnka S; Uthaipibull C; Svasti S; Fucharoen S; Srichairatanakool S Biomed Pharmacother; 2018 Dec; 108():1694-1702. PubMed ID: 30372872 [TBL] [Abstract][Full Text] [Related]
26. Iron and oxidative stress in cardiomyopathy in thalassemia. Berdoukas V; Coates TD; Cabantchik ZI Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855 [TBL] [Abstract][Full Text] [Related]
27. T-type and L-type Calcium Channel Blockers for the Treatment of Cardiac Iron Overload: An Update. Kumfu S; Chattipakorn SC; Chattipakorn N J Cardiovasc Pharmacol; 2017 Nov; 70(5):277-283. PubMed ID: 28777254 [TBL] [Abstract][Full Text] [Related]
28. Cardiac complications in beta-thalassemia: From mice to men. Kumfu S; Fucharoen S; Chattipakorn SC; Chattipakorn N Exp Biol Med (Maywood); 2017 Jun; 242(11):1126-1135. PubMed ID: 28485683 [TBL] [Abstract][Full Text] [Related]
29. A case of iron overload cardiomyopathy: beneficial effects of iron chelating agent and calcium channel blocker on left ventricular dysfunction. Sugishita K; Asakawa M; Usui S; Takahashi T Int Heart J; 2009 Nov; 50(6):829-38. PubMed ID: 19952479 [TBL] [Abstract][Full Text] [Related]
30. Combined therapy with deferoxamine and deferiprone. Kattamis A Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663 [TBL] [Abstract][Full Text] [Related]
31. MRI imaging and histopathological study of brain iron overload of β-thalassemic mice. Yatmark P; Huaijantug S; Teerapan W; Svasti S; Fucharoen S; Morales NP Magn Reson Imaging; 2019 Sep; 61():267-272. PubMed ID: 31128226 [TBL] [Abstract][Full Text] [Related]
32. Cardioprotective Potential of Iron Chelators and Prochelators. Jansová H; Šimůnek T Curr Med Chem; 2019; 26(2):288-301. PubMed ID: 28933303 [TBL] [Abstract][Full Text] [Related]
33. A novel synthetic compound, deferiprone-resveratrol hybrid (DFP-RVT), promotes hepatoprotective effects and ameliorates iron-induced oxidative stress in iron-overloaded β-thalassemic mice. Li J; Chuljerm H; Settakorn K; Xu H; Ma Y; Korsieporn W; Paradee N; Srichairatanakool S; Koonyosying P Biomed Pharmacother; 2024 Nov; 180():117570. PubMed ID: 39423750 [TBL] [Abstract][Full Text] [Related]
34. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone. Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196 [TBL] [Abstract][Full Text] [Related]
35. Cardioprotective effect of iron chelators. Hershko C; Link G; Konijn AM Adv Exp Med Biol; 2002; 509():77-89. PubMed ID: 12572990 [No Abstract] [Full Text] [Related]
36. Increased sympathovagal imbalance evaluated by heart rate variability is associated with decreased T2* MRI and left ventricular function in transfusion-dependent thalassemia patients. Pattanakuhar S; Phrommintikul A; Tantiworawit A; Konginn S; Srichairattanakool S; Chattipakorn SC; Chattipakorn N Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29330222 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572 [TBL] [Abstract][Full Text] [Related]
38. Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review. Moayedi Esfahani BA; Reisi N; Mirmoghtadaei M Hemoglobin; 2015; 39(2):75-80. PubMed ID: 25643967 [TBL] [Abstract][Full Text] [Related]
39. L-type calcium channel blockers decrease the iron overload-mediated oxidative stress in renal epithelial cells by reducing iron accumulation. Sun L; Lin X; Pornprasert S; Lü X; Ran B; Lin Y Eur J Pharmacol; 2020 Nov; 886():173513. PubMed ID: 32898550 [TBL] [Abstract][Full Text] [Related]
40. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress. Das SK; Patel VB; Basu R; Wang W; DesAulniers J; Kassiri Z; Oudit GY J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28115312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]